Introduction
Lung cancer represents one of the most common and serious malignancies, characterized by high incidence and mortality. The disease is marked by rapid proliferation, early metastatic dissemination, and frequently delayed diagnosis, which significantly limits therapeutic options. Annual mortality reaches approximately 5,000 cases [1], making lung cancer the leading cause of cancer-related death in the Czech Republic. The five-year overall survival rate ranges between 15–20%, with the stage at diagnosis being a critical prognostic factor.
In recent years, a modest decline in mortality has been observed, primarily due to advances in molecularly targeted therapies, immunotherapy, and improved diagnostic methods. The growing emphasis on personalized treatment approaches and the use of combination therapeutic regimens has contributed to improved clinical outcomes in selected patient subpopulations.
The LUNAR (LUNg cAncer Registry) is designed as a systematic database for collecting clinical data on patients with lung cancer, the therapeutic modalities used, and their outcomes. Its goal is to support clinical research and optimize treatment strategies in real-world clinical practice.
About the Project
LUNAR is a multicenter registry focused on monitoring patients with lung cancer, aiming to provide deeper insight into this serious disease through the systematic collection and analysis of clinical data. The project gathers information on disease progression, selected therapeutic approaches, their efficacy across different lines of treatment, and the potential of various treatment combinations.
The project is conducted under the professional auspices of the Czech Medical Association of J. E. Purkyně, specifically its organizational branch—the Czech Pneumological and Phthisiological Society. Comprehensive Cancer Centers across the Czech Republic actively participate in its implementation.
LUNAR represents a unique platform that bridges clinical practice and scientific research. The collected data have the potential to support the development of new therapeutic strategies, contribute to personalized care, and lead to tangible improvements in the prognosis of patients with lung cancer.
Objectives
Primary Objective:
- Collection of epidemiological and clinical data on patients with lung cancer in the Czech Republic
Secondary Objectives:
- Assessment of treatment quality – evaluation of overall survival (OS) and progression-free survival (PFS)
- Analysis of response to individual treatment modalities in real-world clinical practice (real-world data)
Guarantee
Expert Guarantee
The registry operates under the auspices of the Czech Pneumological and Phthisiological Society of the Czech Medical Association of J. E. Purkyně.
The registry is supervised by Assoc. Prof. Martin Svatoň, MD, Ph.D.
Project Management
- Institute of Biostatistics and Analyses, Ltd., a spin-off company of Masaryk University, ensures management and other service activities for this project
- Mgr. Adéla Vojkůvková, Project Manager
- Ing. Petr Brabec, Ph.D., Managing Director